The Basque biopharmaceutical company Histocell and the company Cardiva join forces to introduce the innovative wound care product Reoxcare throughout the Spanish healthcare system.
The Basque biopharmaceutical company Histocell, specialised in regenerative medicine, has developed and manufactures Reoxcare, an antioxidant treatment of natural ingredients for the healing of chronic wounds, after years of research into oxidative stress.
Histocell produces Reoxcare in its medical device manufacturing plant inaugurated in 2018 in Larrabetzu, Bizkaia. Through this agreement with Cardiva, specialised in the the commercialisation of medical devices in the hospital system, Histocell strengthens its commercial capacity throughout the national territory.
“This is a very important agreement for Histocell that reinforces the company’s strategy focused on the development and manufacture of innovative products for regenerative medicine. Histocell is committed to collaborating with leading companies in the distribution of healthcare products, as is the case of Cardiva, for the commercialisation of its product Reoxcare”, Julio Font – Histocell
Cardiva will distribute Reoxcare throughout Spain from its central warehouse, located in the business area of Lezama. The company’s president, Ignacio Vega, emphasises that “this agreement responds to Cardiva’s commitment to provide patients with innovative medical solutions that improve health and to be at the forefront of the latest advances in the therapeutic areas in which we are involved”. Thanks to this union, the innovative product Reoxcare will enter the entire national territory. So far it is marketed in the Basque Country, Navarre and Galicia, with Osakidetza (Basque Health Service) and Osasunbidea (Navarre Health Service) being the main customers today.
In 2020, Reoxcare has reached 60% of the Basque Country’s health system’s OSIs, and is also present in the Pamplona Health Area, the largest in the Navarre region. Thus, it has managed to double sales compared to 2019, sales that it expects triple in 2021 thanks to the agreement with Cardiva.
With this agreement, Histocell continues to expand its network of distributors present in different international markets such as the Netherlands, Italy, Colombia, Chile and Mexico, which will soon be joined by China, Singapore, Malaysia and Egypt.